Who are Levosimendan infusion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levosimontane injection, Levosimendan Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levosimendan-infusion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Levosimendan infusion — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Levosimendan infusion (Levosimendan infusion) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium sensitizer / inodilator. Area: Cardiovascular.

marketed Calcium sensitizer / inodilator Cardiac troponin C; ATP-sensitive potassium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Levosimendan infusion (Levosimendan infusion) — AHEPA University Hospital. Levosimendan is a calcium sensitizer that increases the force of cardiac muscle contraction without increasing oxygen consumption, while also causing vasodilation through opening of ATP-sensitive potassium channels.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Levosimendan infusion TARGET	Levosimendan infusion	AHEPA University Hospital	marketed	Calcium sensitizer / inodilator	Cardiac troponin C; ATP-sensitive potassium channels
Levosimontane injection	Levosimontane injection	Qilu Hospital of Shandong University	marketed	Calcium sensitizer / inotropic agent	Cardiac troponin C; ATP-sensitive potassium channels
Levosimendan Injection	Levosimendan Injection	Peking University Third Hospital	marketed	Calcium sensitizer / inotropic agent	Cardiac troponin C; ATP-sensitive potassium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium sensitizer / inodilator class)

AHEPA University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levosimendan infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/levosimendan-infusion. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing